MYOV News and Press, Myovant Sciences Ltd. From 04/29/20

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

Abstracts accepted for presentation in oral and poster sessions at the 2020 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting Treatment with relugolix combination therapy resulted in significant improvements in pain and quality of life i...

Myovant Sciences (NYSE: MYOV) fired a shot across the bow of AbbVie (NYSE: ABBV) when it released phase 3 clinical trial results on April 22. The study evaluating relugolix as a treatment for pain caused by endometriosis met two co-primary endpoints and a slate of secondary endpoints. Re...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most i...

Baird notes that clinical-stage biopharmaceutical firm Myovant Sciences ( MYOV +3.2% ) submitted its New Drug Application for relugolix in patients with advanced prostate cancer - and says that more catalysts can drive a continued share-price rebound during the pandemic. More news on: ...

Myovant Sciences (NYSE: MYOV ) is up  7%  premarket on light volume in reaction to positive results from a Phase 3 clinical trial, SPIRIT 2 , evaluating once-daily relugolix combo therapy (relugolix 40 mg plus estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in women with end...

Co-primary endpoints met with 75.2% response rate for dysmenorrhea (menstrual pain) (p < 0.0001) and 66.0% response rate for non-menstrual pelvic pain (p < 0.0001) Women receiving relugolix combination therapy, on average, had a 75.1% reduction on the Numerical Rating Scale for...

Gainers: DKL   +24.8% .   SNAP   +19.1% . TRMD   +16.8% . GME   +7.3% . MYOV   +6.8% . More news on: Delek Logistics Partners, LP, Snap Inc., TORM plc, Stocks on the move, , Read more ...

BASEL, Switzerland, April 21, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women's health and prostate cancer, today announced it will hold a webcast and conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Ti...